Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment

Betsy Goodfellow | July 3, 2024 | News story | Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology 

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for IV infusion) for the treatment of adult patients with early symptomatic Alzheimer’s disease (AD).

The drug is now approved for this indication, including people with mild cognitive impairment (MCI) and those with mild dementia stage AD with confirmed amyloid pathology.

Once monthly treatment with the drug is the ‘first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions’, according to the press release.

Advertisement

Anne White, executive vice president and president of Lilly Neuroscience at Eli Lilly and Company, commented: “Kisunla demonstrated very meaningful results for people with early symptomatic AD, who urgently need effective treatment options. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership with others to improve detection and diagnosis. Our deepest thanks to the patients and their loved ones for participating in our clinical programmes, and to Lilly scientists and collaborators persevering over decades of research. Each year, more and more people are at risk for this disease, and we are determined to make life better for them.”

Betsy Goodfellow

Related Content

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

The Gateway to Local Adoption Series

Latest content